BioTelemetry Inc (NASDAQ:BEAT) Director Kirk E. Gorman sold 625 shares of BioTelemetry stock in a transaction on Monday, September 17th. The stock was sold at an average price of $62.30, for a total transaction of $38,937.50. Following the completion of the sale, the director now owns 173,940 shares of the company’s stock, valued at approximately $10,836,462. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of BEAT traded up $1.54 during midday trading on Friday, hitting $53.31. 500,750 shares of the stock traded hands, compared to its average volume of 395,296. BioTelemetry Inc has a 1-year low of $23.30 and a 1-year high of $66.02. The company has a market cap of $2.11 billion, a price-to-earnings ratio of 54.96, a price-to-earnings-growth ratio of 4.26 and a beta of 1.41. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.12 and a current ratio of 2.29.

BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Wednesday, July 25th. The medical research company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.15. BioTelemetry had a negative net margin of 0.39% and a positive return on equity of 18.02%. The company had revenue of $101.36 million during the quarter, compared to the consensus estimate of $95.87 million. During the same quarter in the previous year, the company posted $0.23 earnings per share. The company’s revenue for the quarter was up 74.4% compared to the same quarter last year. Analysts predict that BioTelemetry Inc will post 1.51 EPS for the current year.

BEAT has been the subject of a number of research analyst reports. SunTrust Banks lifted their price target on shares of BioTelemetry to $67.00 and gave the stock a “buy” rating in a research note on Friday, August 31st. Lake Street Capital boosted their target price on shares of BioTelemetry from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, July 26th. Raymond James boosted their target price on shares of BioTelemetry from $57.00 to $66.00 and gave the company an “outperform” rating in a research note on Friday, September 14th. Benchmark boosted their target price on shares of BioTelemetry from $46.00 to $54.00 and gave the company a “buy” rating in a research note on Wednesday, June 20th. Finally, BidaskClub lowered shares of BioTelemetry from a “buy” rating to a “hold” rating in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $61.50.

Several institutional investors and hedge funds have recently made changes to their positions in BEAT. LPL Financial LLC lifted its holdings in BioTelemetry by 15.1% in the first quarter. LPL Financial LLC now owns 20,884 shares of the medical research company’s stock worth $648,000 after purchasing an additional 2,739 shares during the period. Castleark Management LLC acquired a new stake in BioTelemetry in the second quarter worth about $13,712,000. Swiss National Bank lifted its holdings in BioTelemetry by 5.6% in the second quarter. Swiss National Bank now owns 56,600 shares of the medical research company’s stock worth $2,547,000 after purchasing an additional 3,000 shares during the period. Legal & General Group Plc lifted its holdings in BioTelemetry by 2.9% in the first quarter. Legal & General Group Plc now owns 57,741 shares of the medical research company’s stock worth $1,778,000 after purchasing an additional 1,653 shares during the period. Finally, Natixis lifted its holdings in BioTelemetry by 1.3% in the second quarter. Natixis now owns 319,024 shares of the medical research company’s stock worth $14,356,000 after purchasing an additional 4,224 shares during the period. 93.82% of the stock is owned by institutional investors.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Recommended Story: Trading Strategy

Insider Buying and Selling by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.